Gilead acquires PARP1, autoimmune biotech XinThera

Gilead’s dealmaking spree, part of biopharma’s “blistering” M&A this year, continued on Tuesday with a consummation of oncology and inflammation startup XinThera. After deals for UK startup MiroBio, a Jounce antibody and Tmunity — while passing on Pionyr — Gilead is now further expanding beyond its HIV products with a…

...

Click to view original post